Patents Examined by Sean E Aeder
  • Biomarkers and combination therapies using oncolytic virus and immunomodulation
    Patent number: 10238698
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 26, 2019
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W. K. Alfred Yung, Amy Heimberger
  • Heterodimeric antibodies that bind CD3 and PSMA
    Patent number: 10227410
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: March 12, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, John Desjarlais, Seung Chu
  • Modulation of T cells with bispecific antibodies and FC fusions
    Patent number: 10227411
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 12, 2019
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
  • Compositions and methods of treating cancer harboring PIKC3A mutations
    Patent number: 10221459
    Abstract: A method of treating cancer cells having mutated PIK3CA gene or protein of a subject in need thereof includes administering to the subject a therapeutically effective amount of an inhibitor of one or more enzymes of the glutamine metabolism pathway.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 5, 2019
    Assignee: Case Western Reserve University
    Inventors: Zhengne Wang, Yujun Hao
  • Modulation of immunity and CEACAM1 activity
    Patent number: 10188760
    Abstract: The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 29, 2019
    Inventor: Gal Markel
  • Antibody fragments for detecting cancer and methods of use
    Patent number: 10166304
    Abstract: The present invention relates to diagnostic and therapeutic agents comprising recombinant antibody fragments to bind a protein associated with cancer and methods of use of these diagnostic and therapeutic agents.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 1, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Jayanth Panyam, Stephen Kalscheuer
  • Compositions and methods for treatment of non-hodgkins lymphoma
    Patent number: 10166276
    Abstract: The present invention provides recombinant peptides comprising a B cell receptor (BCR) or a fragment thereof, nucleotide molecules encoding same, and vaccines and vectors comprising same; and methods of treating, inducing an immune response against, inducing a regression of, and suppressing a formation of a lymphoma, comprising administering same. The present invention also provides methods of inducing a humoral immune response in an animal against an antigen, comprising administering to the animal a fusion peptide comprising an LLO protein or fragment thereof fused to the antigen.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: January 1, 2019
    Assignee: The Trustees of the University of Philadelphia
    Inventors: Yvonne Paterson, Paul Neeson
  • Bispecific HER2 antibodies
    Patent number: 10160812
    Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: December 25, 2018
    Assignee: MedImmune, LLC
    Inventors: John Li, Nazzareno Dimasi, Steven Coats, Melissa Damschroder, Changshou Gao, Godfrey Rainey, Cuihua Gao, Dorin Toader, Lakshmaiah Gingipalli, Fengjiang Wang, Ryan Fleming, Binyam Bezabeh, Andy Qingan Yuan, Srinath Kasturirangan
  • Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
    Patent number: 10151755
    Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 11, 2018
    Assignees: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Lung cancer diagnosis marker, antibody and application thereof
    Patent number: 10144771
    Abstract: A human lung cancer marker N3G4, and use of the same as human lung cancer marker is disclosed. Hybridoma cells which produce anti-N3G4 monoclonal antibodies, and the secreted monoclonal antibody LC128, and use of LC128 for the preparation of a diagnostic agent for lung cancer are also disclosed. Kits for in vitro diagnosis comprising the monoclonal antibody LC128 and methods for detecting tumor markers in lung tissue by using the monoclonal antibody LC128 are also disclosed.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 4, 2018
    Inventor: Chong Li
  • Semaphorin 3A as a diagnostic marker for urothelial cancer
    Patent number: 10139412
    Abstract: The present invention is directed to methods and kits useful for diagnosis and/or prognosis of urothelial cancer in a subject. The present invention further relates to methods of assessing severity of cancer and methods of determining efficacy of a treatment for cancer. The methods and kits of the invention comprise determining the levels of semaphorin 3A in a biological sample of a subject.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 27, 2018
    Assignees: The Fund for Medical Research, Development of Infrastructure and Health Services—Bnai Zion Medical Center, Technion Research and Development Foundation Limited
    Inventors: Zahava Vadasz, Sarel Halachmi, Jacob Rubinstein, Ofer Nativ, Elias Toubi
  • Profiling peptides and methods for sensitivity profiling
    Patent number: 10132797
    Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 20, 2018
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
  • Detection of chromosomal region copy number changes to diagnose melanoma
    Patent number: 10119170
    Abstract: This invention provides methods of detecting melanoma. The methods comprises detecting a gain or loss of certain chromosomal regions that undergo copy number changes in melanoma.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: November 6, 2018
    Assignee: The Regents of the University of California
    Inventors: Boris Bastian, Daniel Pinkel
  • Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
    Patent number: 10119171
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: November 6, 2018
    Assignee: InBioMotion S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
    Patent number: 10114022
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: October 30, 2018
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Heterodimeric proteins
    Patent number: 10106624
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 23, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, John Desjarlais, Rumana Rashid
  • Antibodies comprising chimeric constant domains
    Patent number: 10106610
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 23, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Blocking CD38 using anti-CD38 F(ab?)2 to protect NK cells
    Patent number: 10106620
    Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 23, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Janssen Biotech, Inc.
    Inventors: Richard W. Childs, Maria Berg, Luis Espinoza Calderon, Kate Sasser, Ricardo Attar
  • Diagnostic method
    Patent number: 10107814
    Abstract: The invention provides a method of detecting a subject suffering from, or at risk of suffering from, bladder cancer the method comprising i) providing a body fluid sample isolated from a subject; ii) isolating cells from said sample to provide a cell sample; iii) contacting the sample with a specific binding member capable of binding to a minichromosome maintenance (MCM) polypeptide(s); iv) determining the binding of said specific binding member to the cell sample; v) counting those cells in said cell sample which bound to said specific binding member to provide a cell count; vi) determining, based on the cell count, whether the subject has, or is at risk of having, bladder cancer.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: October 23, 2018
    Inventors: David Galloway, Nick Coleman
  • Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
    Patent number: 10098963
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: October 16, 2018
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy